BRPI0618552B8 - compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos - Google Patents

compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos

Info

Publication number
BRPI0618552B8
BRPI0618552B8 BRPI0618552A BRPI0618552A BRPI0618552B8 BR PI0618552 B8 BRPI0618552 B8 BR PI0618552B8 BR PI0618552 A BRPI0618552 A BR PI0618552A BR PI0618552 A BRPI0618552 A BR PI0618552A BR PI0618552 B8 BRPI0618552 B8 BR PI0618552B8
Authority
BR
Brazil
Prior art keywords
compounds
oxygen
linked
synthesis
pharmaceutical composition
Prior art date
Application number
BRPI0618552A
Other languages
English (en)
Inventor
Poulsen Anders
Deodaunia William Anthony
Hsia Angeline Lee Cheng
T Sun Eric
Kumar Mysore Nagaraj Harish
Blanchard Stéphanie
Ling Evelyn Tan Yee
Original Assignee
Cell Therapeutics Inc
Cti Biopharma Corp
Sstarbio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc, Cti Biopharma Corp, Sstarbio Pte Ltd filed Critical Cell Therapeutics Inc
Publication of BRPI0618552A2 publication Critical patent/BRPI0618552A2/pt
Publication of BRPI0618552B1 publication Critical patent/BRPI0618552B1/pt
Publication of BRPI0618552B8 publication Critical patent/BRPI0618552B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

derivados de pirimidina ligados ao oxigênio. a presente invenção refere-se aos compostos de pirimidina que são úteis como agentes antiproliferativos. mais particularmente, a presente invenção refere-se aos compostos de pirimidina ligados ao oxigênio e substituídos, aos métodos para a sua preparação, às composições farmacêuticas que contêm estes compostos e aos usos destes compostos no tratamento de distúrbios proliferativos. estes compostos podem ser úteis como medicamentos para o tratamento de diversos distúrbios proliferativos, incluindo os tumores e os cânceres, bem como outros distúrbios ou condições relacionadas às, ou associadas com as, cinases.
BRPI0618552A 2005-11-16 2006-11-15 compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos BRPI0618552B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US73683805P 2005-11-16 2005-11-16
US60/736.838 2005-11-16
US81733906P 2006-06-30 2006-06-30
US60/817.339 2006-06-30
US85128306P 2006-10-13 2006-10-13
US60/851.283 2006-10-13
PCT/SG2006/000352 WO2007058627A1 (en) 2005-11-16 2006-11-15 Oxygen linked pyrimidine derivatives

Publications (3)

Publication Number Publication Date
BRPI0618552A2 BRPI0618552A2 (pt) 2011-09-06
BRPI0618552B1 BRPI0618552B1 (pt) 2021-04-06
BRPI0618552B8 true BRPI0618552B8 (pt) 2021-05-25

Family

ID=38048928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618552A BRPI0618552B8 (pt) 2005-11-16 2006-11-15 compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos

Country Status (20)

Country Link
US (5) US8143255B2 (pt)
EP (1) EP1951729B1 (pt)
JP (2) JP5380073B2 (pt)
KR (5) KR20080090390A (pt)
CN (2) CN101365703B (pt)
AT (1) ATE469158T1 (pt)
AU (2) AU2006316071B2 (pt)
BR (1) BRPI0618552B8 (pt)
CA (2) CA2629455C (pt)
CY (1) CY1116156T1 (pt)
DE (1) DE602006014579D1 (pt)
DK (2) DK1951730T3 (pt)
ES (2) ES2346791T3 (pt)
MY (1) MY148072A (pt)
NZ (1) NZ568325A (pt)
PH (1) PH12012501003B1 (pt)
PL (1) PL1951729T3 (pt)
PT (2) PT1951729E (pt)
TW (3) TWI506029B (pt)
WO (2) WO2007058627A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2628283C (en) 2005-11-01 2017-06-27 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en) * 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
MX2009000456A (es) 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
AR065583A1 (es) * 2007-03-01 2009-06-17 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos y composicion farmaceutica
WO2008140420A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyrimidine derivatives
WO2008140419A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyridyl substituted pyrimidine derivatives
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2283024B1 (en) * 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CN102282148B (zh) * 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
DK2376500T3 (en) * 2008-12-11 2015-05-04 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt
DK2454266T3 (da) * 2009-07-15 2013-09-08 Cell Therapeutics Inc 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt
UA115523C2 (uk) * 2010-02-05 2017-11-27 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Тверді форми макроциклічних інгібіторів кінази
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
CN102757448B (zh) * 2011-04-26 2016-04-06 中南大学 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
UA113186C2 (xx) * 2011-09-30 2016-12-26 Макроциклічні інгібітори lrrk2 кінази
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
EP2970213A4 (en) * 2013-03-14 2016-09-07 Concert Pharmaceuticals Inc PACRITINIB DEUTÉRIÉ
ES2637721T3 (es) * 2013-05-06 2017-10-16 Merck Patent Gmbh Macrociclos como inhibidores de quinasa
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
FR3025200B1 (fr) 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
FR3025199B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
TW201625639A (zh) 2014-09-17 2016-07-16 腫瘤設計公司 巨環ｌｒｒｋ２激酶抑制劑
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
WO2016149031A1 (en) * 2015-03-18 2016-09-22 Newave Pharmaceutical Llc Covalent inhibitors of cdk-7
CN105017282B (zh) * 2015-08-28 2017-11-07 苏州明锐医药科技有限公司 帕克替尼的制备方法
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法
JP6878418B2 (ja) * 2015-09-28 2021-05-26 シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． 移植片拒絶反応の処置方法
ES2819869T3 (es) * 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
ES2941687T3 (es) * 2016-03-24 2023-05-24 Cothera Bioscience Inc Tratamiento del cáncer con TG02
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
MX2020001875A (es) * 2017-08-18 2020-07-29 Tragara Pharmaceuticals Inc Forma polimorfica de tg02.
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. Tnik modulators, conjugates, and uses thereof
CN108864145B (zh) * 2018-09-14 2021-03-30 兆科（广州）肿瘤药物有限公司 一种氧联嘧啶衍生物的纯化方法
JP2022513320A (ja) * 2018-10-01 2022-02-07 オハイオ・ステイト・イノベーション・ファウンデーション Ｆｌｔ３が変異した血液のがんを処置する方法
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) * 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
CN111989332B (zh) * 2018-12-19 2022-07-26 凯复(苏州)生物医药有限公司 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
ES3034869T3 (en) * 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CN113583020B (zh) * 2020-04-30 2022-04-22 百极弘烨（广东）医药科技有限公司 一种jak2抑制剂及应用
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
WO2022056092A1 (en) * 2020-09-11 2022-03-17 Cti Biopharma Corp. Methods of treating viral infection
CN115490705B (zh) * 2021-06-18 2025-04-01 成都凡诺西生物医药科技有限公司 N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) * 2022-01-28 2023-07-25 山东大学 一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
CN117447407B (zh) * 2023-12-19 2024-06-11 潍坊医学院 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
KR100569620B1 (ko) 1997-06-27 2006-04-11 시바 스페셜티 케미칼스 홀딩 인크. 루테늄 및 오스뮴 촉매
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004039809A1 (ja) * 2002-10-29 2004-05-13 Banyu Pharmaceutical Co., Ltd. 新規キノキサリノン誘導体
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) * 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
DE602004012891T2 (de) * 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
UA83880C2 (en) * 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. 3-cyano-quinoline derivatives with antiproliferative activity
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) * 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness

Also Published As

Publication number Publication date
US8415338B2 (en) 2013-04-09
KR101568801B1 (ko) 2015-11-12
JP5380073B2 (ja) 2014-01-08
CY1116156T1 (el) 2017-02-08
KR20140037256A (ko) 2014-03-26
KR101513492B1 (ko) 2015-04-20
NZ568325A (en) 2011-05-27
JP2009517344A (ja) 2009-04-30
WO2007058627A1 (en) 2007-05-24
KR20140117679A (ko) 2014-10-07
MY148072A (en) 2013-02-28
TW201418263A (zh) 2014-05-16
BRPI0618552A2 (pt) 2011-09-06
PH12012501003A1 (en) 2012-10-29
TW200736262A (en) 2007-10-01
CA2629455C (en) 2017-01-03
WO2007058628A1 (en) 2007-05-24
US20090075999A1 (en) 2009-03-19
US8153632B2 (en) 2012-04-10
DK1951730T3 (da) 2010-09-27
ES2346791T3 (es) 2010-10-20
TWI407961B (zh) 2013-09-11
ATE469158T1 (de) 2010-06-15
CA2629455A1 (en) 2007-05-24
US20130172338A1 (en) 2013-07-04
HK1124040A1 (en) 2009-07-03
US20090258886A1 (en) 2009-10-15
EP1951729A1 (en) 2008-08-06
US8143255B2 (en) 2012-03-27
CN101360751B (zh) 2011-09-14
BRPI0618552B1 (pt) 2021-04-06
PT1951730E (pt) 2010-08-27
CA2629443A1 (en) 2007-05-24
US9573964B2 (en) 2017-02-21
KR20080086443A (ko) 2008-09-25
KR20140037257A (ko) 2014-03-26
CN101365703B (zh) 2013-11-06
AU2006316071A1 (en) 2007-05-24
CN101365703A (zh) 2009-02-11
KR101576159B1 (ko) 2015-12-09
PH12012501003B1 (en) 2018-04-06
AU2006316071B2 (en) 2011-02-17
CA2629443C (en) 2016-12-13
CN101360751A (zh) 2009-02-04
US20120196855A1 (en) 2012-08-02
US9133214B2 (en) 2015-09-15
KR101499594B1 (ko) 2015-03-09
JP2009515954A (ja) 2009-04-16
KR20080090390A (ko) 2008-10-08
EP1951729A4 (en) 2009-09-23
EP1951729B1 (en) 2014-06-25
ES2506040T3 (es) 2014-10-13
DK1951729T3 (da) 2014-10-06
TWI506029B (zh) 2015-11-01
TWI525096B (zh) 2016-03-11
JP5225856B2 (ja) 2013-07-03
PT1951729E (pt) 2014-10-02
AU2006316072B2 (en) 2011-12-22
AU2006316072A1 (en) 2007-05-24
TW200738735A (en) 2007-10-16
PL1951729T3 (pl) 2015-02-27
US20120142680A1 (en) 2012-06-07
HK1123282A1 (en) 2009-06-12
DE602006014579D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0709680B8 (pt) derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0716981B8 (pt) inibidores de cinase úteis para tratamento de doenças proliferativas, e composição farmacêutica
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
ECSP13012852A (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a.
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CELL THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: CTI BIOPHARMA CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/11/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF